Remove 2018 Remove Chemotherapy Remove Vaccines
article thumbnail

Governments and pharma relationships and implications for antimicrobial resistance

Pharmaceutical Technology

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.

article thumbnail

ESMO 2022: data updates push immunotherapy’s scope in cervical cancer

Pharmaceutical Technology

In 2018, the World Health Organisation (WHO) reported that 570,000 women were diagnosed with cervical cancer, of which 311,000 died of the disease. Early-stage cervical cancer patients achieve good recovery through surgery and concurrent chemotherapy, but treatment options are scarce for those with recurrent metastatic cervical cancer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA fast-tracks Leap’s gastric cancer immunotherapy

pharmaphorum

The FDA now says it will fast track review of DKN-01 as a second-line therapy for DKK-positive G/GEJ cancers after prior fluoropyrimidine- and platinum- containing chemotherapy as well as anti-HER2 drugs if those have been deemed appropriate. The post FDA fast-tracks Leap’s gastric cancer immunotherapy appeared first on.

FDA 72
article thumbnail

Sanofi, Regeneron prep filings for Libtayo in cervical cancer

pharmaphorum

A phase 3 trial of the PD-1 inhibitor in cervical cancer patients who had progressed after first-line chemotherapy has been stopped early after an interim look at the data showed that the drug cut mortality by 31% compared to second-line chemo. The median overall survival with Libtayo (cemiplimab) was 12 months, compared to 8.5

article thumbnail

2020 review – Pharma’s progress outside of COVID-19

pharmaphorum

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. months in patients treated with chemotherapy. In the 500 patient trial, patients treated with Trodelvy lived for a median of 12.1 months, compared with 6.7

FDA 96
article thumbnail

Microbiome therapies: a maturing movement

European Pharmaceutical Review

How do you envision microbiome therapies complementing existing cancer treatments, such as chemotherapy and immunotherapy? He has also held the role of Vice President and Therapeutic Area Head, Vaccine Clinical Research at Merck & Co. Science 2018 Available from: [link] Davar D. Internet] European Commission. Science, 2021.

article thumbnail

Revitalising in-hospital drug manufacturing

Hospital Pharmacy Europe

New responsibilities, new arenas The potential for in-hospital manufacturing is further developing due to the new responsibilities assigned to hospital pharmacy staff, such as centralised preparation of chemotherapies and drugs for clinical trials, extemporaneous production of radiopharmaceuticals and cellular therapies, to name but a few.